<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05085444</url>
  </required_header>
  <id_info>
    <org_study_id>CD19/BCMA-002</org_study_id>
    <nct_id>NCT05085444</nct_id>
  </id_info>
  <brief_title>A Study of CD19/BCMA Chimeric Antigen Receptor T Cells Therapy for Patients With Refractory Scleroderma</brief_title>
  <official_title>A Study of CD19/BCMA Chimeric Antigen Receptor T Cells Therapy for Patients With Refractory Scleroderma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zhejiang University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Yake Biotechnology Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Zhejiang University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Study of CD19/BCMA Chimeric Antigen Receptor T Cells Therapy for Patients With Refractory&#xD;
      Scleroderma&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Autoimmune diseases only show local pathological damage, but more often systemic lesions. If&#xD;
      not diagnosed and treated in time or poorly controlled, a risk of disability or even death as&#xD;
      the course of the disease progresses. Studies have shown that B cells can present their own&#xD;
      antigens to autoimmune T cells to promote the release of inflammatory factors, or they can&#xD;
      differentiate into plasma cells to release autoantibodies, and play an important role in the&#xD;
      occurrence and progression of autoimmune diseases. In recent years, it has become a major&#xD;
      research focus to deplete B cells in patients or inhibit B cell function. This research&#xD;
      focuses on CAR-T cells killing B cells. This fully reflects the application prospects of&#xD;
      CAR-T cells in autoimmune diseases.&#xD;
&#xD;
      Based on the current research progress, our center intends to conduct research on the safety&#xD;
      and effectiveness of CD19/BCMA CAR-T cells in the treatment of refractory scleroderma&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 8, 2021</start_date>
  <completion_date type="Anticipated">October 8, 2024</completion_date>
  <primary_completion_date type="Anticipated">October 8, 2024</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Dose-limiting toxicity (DLT)</measure>
    <time_frame>Baseline up to 28 days after CD19/BCMA CAR T-cells infusion</time_frame>
    <description>Adverse events assessed according to NCI-CTCAE v5.0 criteria</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of treatment-emergent adverse events (TEAEs)</measure>
    <time_frame>Up to 90 days after CD19/BCMA CAR T-cells infusion</time_frame>
    <description>Incidence of treatment-emergent adverse events [Safety and Tolerability]</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Concentration of CAR-T cells</measure>
    <time_frame>From admission to the end of the follow-up, up to 2 years</time_frame>
    <description>In peripheral blood</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate, ORR</measure>
    <time_frame>In 3 months of CD19/BCMA CAR-T cell infusion</time_frame>
    <description>Proportion of subjects with complete or partial remission</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease control rate, DCR</measure>
    <time_frame>From Day 28 CD19/BCMA CAR-T infusion up to 2 years</time_frame>
    <description>The percentage of patients with remission and stable disease after treatment in the total evaluable cases.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of remission, DOR</measure>
    <time_frame>24 months post CD19/BCMA CAR-T cells infusion</time_frame>
    <description>The time from the first assessment of remission or partial remission of the disease to the first assessment of disease progression or death from any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival, PFS</measure>
    <time_frame>24 months post CD19/BCMA CAR-Tcells infusion</time_frame>
    <description>The time from cell reinfusion to the first assessment of disease progression or death from any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival, OS</measure>
    <time_frame>From CD19/BCMA CAR-T infusion to death，up to 2 years</time_frame>
    <description>The time from the cell reinfusion to death due to any cause</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">9</enrollment>
  <condition>Scleroderma</condition>
  <condition>Autoimmune Diseases</condition>
  <arm_group>
    <arm_group_label>Treatment of Scleroderma</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Experimental：Administration of CD19/BCMA CAR T-cells A dose levels of 1-4*10E6/kg are administrated for each subject.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Assigned Interventions CD19/BCMA CAR T-cells</intervention_name>
    <description>Drug: CD19/BCMA CAR T-cells Each subject receive CD19/BCMA CAR T-cells by intravenous infusion Other Name: CD19/BCMA CAR T-cells injection</description>
    <arm_group_label>Treatment of Scleroderma</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Scleroderma with positive CD19/BCMA expression , and the conventional treatment is not&#xD;
             effective and (or) no effective treatment&#xD;
&#xD;
          2. Estimated survival time&gt; 12 weeks;&#xD;
&#xD;
          3. Patients had a negative urine pregnancy test before the start of administration and&#xD;
             agreed to take effective contraceptive measures during the test period until the last&#xD;
             follow-up;&#xD;
&#xD;
          4. Patients or their legal guardians volunteer to participate in the study and sign the&#xD;
             informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subjects with any of the following exclusion criteria were not eligible for this&#xD;
             trial:&#xD;
&#xD;
               1. History of craniocerebral trauma, conscious disturbance, epilepsy,&#xD;
                  cerebrovascular ischemia, and cerebrovascular, hemorrhagic diseases;&#xD;
&#xD;
               2. Electrocardiogram shows prolonged QT interval, severe heart diseases such as&#xD;
                  severe arrhythmia in the past;&#xD;
&#xD;
               3. Pregnant (or lactating) women;&#xD;
&#xD;
               4. Patients with severe active infections (excluding simple urinary tract infection&#xD;
                  and bacterial pharyngitis);&#xD;
&#xD;
               5. Active infection of hepatitis B virus or hepatitis C virus;&#xD;
&#xD;
               6. Concurrent therapy with systemic steroids within 2 weeks prior to screening,&#xD;
                  except for the patients recently or currently receiving in haled steroids;&#xD;
&#xD;
               7. Creatinine&gt;2.5mg/dl, or ALT / AST &gt; 3 times of normal amounts, or bilirubin&gt;2.0&#xD;
                  mg/dl;&#xD;
&#xD;
               8. Other uncontrolled diseases that were not suitable for this trial;&#xD;
&#xD;
               9. Patients with HIV infection;&#xD;
&#xD;
              10. Any situations that the investigator believes may increase the risk of patients&#xD;
                  or interfere with the results of study&#xD;
&#xD;
              11. Platelets ≥30×10E9/L, and absolute lymphocyte count ≥1.0×10E9/L&#xD;
&#xD;
              12. Methylprednisolone (maximum dose 1mg/kg) or prednisone (maximum dose 1.25mg/kg)&#xD;
                  instead of immunosuppressive agents to control the disease.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>He Huang, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>First Affiliated Hospital of Zhejiang University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>He Huang, PhD</last_name>
    <phone>86-13605714822</phone>
    <email>hehuangyu@126.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Yongxian Hu, PhD</last_name>
    <phone>86-15957162012</phone>
    <email>huyongxian2000@aliyun.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>The First Affiliated Hospital, College of Medicine, Zhejiang University</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310003</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>He Huang, PhD</last_name>
      <phone>86-13605714822</phone>
      <email>hehuangyu@126.com</email>
    </contact>
    <contact_backup>
      <last_name>Yongxian Hu, PhD</last_name>
      <phone>86-15957162012</phone>
      <email>huyongxian2000@aliyun.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>October 11, 2021</study_first_submitted>
  <study_first_submitted_qc>October 11, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 20, 2021</study_first_posted>
  <last_update_submitted>October 11, 2021</last_update_submitted>
  <last_update_submitted_qc>October 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Zhejiang University</investigator_affiliation>
    <investigator_full_name>He Huang</investigator_full_name>
    <investigator_title>Clinical Professor</investigator_title>
  </responsible_party>
  <keyword>Scleroderma</keyword>
  <keyword>CD19 CAR T-cell therapy</keyword>
  <keyword>BCMA CAR T-cell therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Scleroderma, Systemic</mesh_term>
    <mesh_term>Scleroderma, Diffuse</mesh_term>
    <mesh_term>Scleroderma, Localized</mesh_term>
    <mesh_term>Autoimmune Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

